Promotion by fibronectin of collagen gel contraction mediated by human corneal fibroblasts.
Collagen contraction mediated by corneal fibroblasts (CFs) is implicated in the maintenance of corneal shape. Given that fibronectin is expressed at sites of corneal stromal wounding, we investigated the effect of fibronectin on CF-mediated collagen gel contraction. Human CFs were cultured in a three-dimensional gel of type I collagen in the absence or presence of various extracellular matrix (ECM) components. The contraction of collagen gels mediated by CFs was evaluated by measurement of changes in gel diameter. The formation of stress fibers and focal adhesions in CFs was examined by fluorescence microscopy. The abundance of paxillin, phosphorylated paxillin, integrins alpha5, beta1, and alpha2, and alpha-smooth muscle actin in CFs was examined by immunoblot analysis. Fibronectin promoted CF-mediated collagen gel contraction in a concentration- and time-dependent manner. Other ECM proteins or glycosaminoglycans did not exhibit such an effect. Fibronectin also induced cell spreading, the formation of stress fibers, and the establishment of focal adhesions containing paxillin in CFs cultured in three-dimensional collagen gels. In addition, it increased the amounts of paxillin, phosphorylated paxillin, and integrins alpha5 and beta1 in these cells. The expression of integrin alpha2 and alpha-smooth muscle actin was not affected by fibronectin, however. Furthermore, the peptide GRGDSP (an antagonist of fibronectin receptors) blocked the stimulatory effect of fibronectin on CF-mediated collagen gel contraction. These results suggest that fibronectin promoted CF-mediated collagen gel contraction in a manner dependent on the formation of stress fibers and focal adhesions, the activation of paxillin, and the up-regulation of integrin alpha5beta1. Fibronectin may therefore contribute to the maintenance of corneal shape by CFs during the healing of stromal wounds.
Liu
Yang
Y
Department of Biomolecular Recognition and Ophthalmology, Yamaguchi University School of Medicine, 1-1-1 Minami-Kogushi, Ube City, Yamaguchi 755-8505, Japan.
Yanai
Ryoji
R
Lu
Ying
Y
Kimura
Kazuhiro
K
Nishida
Teruo
T
D000199:Actins / Q000032:analysis; D000368:Aged; D002478:Cells, Cultured; D024042:Collagen Type I / Q000502:physiology*; D003315:Cornea / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D016326:Extracellular Matrix Proteins / Q000378:metabolism; D005136:Eye Proteins / Q000032:analysis; D005260:Female; D005347:Fibroblasts / Q000187:drug effects / Q000502:physiology*; D005353:Fibronectins / Q000494:pharmacology*; D022001:Focal Adhesions / Q000187:drug effects; D005782:Gels; D006801:Humans; D016023:Integrins / Q000032:analysis; D008297:Male; D008856:Microscopy, Fluorescence / Q000379:methods; D008875:Middle Aged; D009842:Oligopeptides / Q000494:pharmacology; D051419:Paxillin / Q000032:analysis; D010766:Phosphorylation; D017469:Receptors, Fibronectin / Q000037:antagonists & inhibitors
D000199:Actins; D024042:Collagen Type I; D016326:Extracellular Matrix Proteins; D005136:Eye Proteins; D005353:Fibronectins; D005782:Gels; D016023:Integrins; D009842:Oligopeptides; D051419:Paxillin; D017469:Receptors, Fibronectin; C058161:glycyl-arginyl-glycyl-aspartyl-seryl-proline; C058347:glycyl-arginyl-glycyl-glutamyl-seryl-proline